Drug Discovery News and Research

RSS

The drug discovery process begins with recognizing a disease or clinical condition in which there is a lack of adequate medical treatment. Once a potential drug has been identified, pre-clinical research can begin. This process includes several stages; the first of which involves identifying and validating the prospective drug’s target through assay development, high throughput screening, hit identification and finally, lead optimization. Once the pre-clinical process is complete, the newly synthesized drug candidate is selected for future clinical development.

UK Government names two leaders to spearhead new Dementia Mission

The UK Government has named two leaders in dementia research to spearhead the ambitious national Mission to tackle dementia, which was launched in memory of the late Dame Barbara Windsor.

20 Mar 2023

£3 million funding to support the development of new antimicrobials for cystic fibrosis patients

Today (16 March 2023), Cystic Fibrosis (CF) Syndicate in Antimicrobial Resistance (AMR) announces a £3 million Collaborative Discovery Programme for drug discovery innovators to accelerate the development of new treatments for people with CF.

20 Mar 2023

Understanding how cells adjust in real time to withstand stresses on our health

Every minute of every day, our body adapts to meet the needs of each moment. When we binge on carbs, exercise, or become sick, chemical reactions inside our cells switch on, slow down, or shift strategy so that we have the energy and strength we need.

14 Mar 2023

CN Bio appoints Deepak Singh as Vice President of Sales and Marketing

CN Bio has today announced that is has appointed Deepak Singh as Vice President of Sales and Marketing.

From CN Bio 14 Mar 2023

Study identifies a potential new treatment approach for acute myeloid leukemia

A team of researchers has discovered a potential therapeutic that can synergize with existing drugs to more effectively kill certain leukemia cells.

8 Mar 2023

Breakthrough drug works against all the main types of primary bone cancer

Researchers at the University of East Anglia have developed a new drug that works against all of the main types of primary bone cancer.

8 Mar 2023

BioInfect: Bringing the best brains to the challenge of antimicrobial resistance

During the conference, we had the chance to catch up with some of the speakers to ask them about their work, as well as what they would be discussing at the 2023 BioInfet Conference.

6 Mar 2023

Antiverse raises funding and demonstrates therapeutic antibody identification with AI-driven drug discovery platform

Antiverse Ltd (Antiverse), a biotechnology company developing a computational antibody drug discovery platform, today announced the successful identification of functional antibody clusters targeting two G-protein-coupled receptors (GPCRs), both displaying versatile binding profiles and nanomolar affinity.

From Antiverse 1 Mar 2023

New funding to accelerate development of potential anti-cancer compound into the clinic

For the past few decades, Dr. Iwao Ojima has been working in his Stony Brook University Department of Chemistry Laboratory and through the Institute of Chemical Biology & Drug Discovery (ICB&DD) to develop next-generation anti-cancer agents.

28 Feb 2023

First small molecules designed to stimulate immune cells against neuroblastoma

An MUSC Hollings Cancer Center research team has created what team members believe to be among the first small molecules designed to stimulate immune cells to fight cancer.

28 Feb 2023

St. Jude researchers show how drug makers can avoid toxicity and resistance

Scientists at St. Jude Children's Research Hospital have demonstrated how drug makers can avoid two key problems: toxicity and resistance.

28 Feb 2023

Five Alarm Bio, Focused on Minimising the Effects of Aging in Humans, Raises Seed Investment

Investors include Cambridge Angels, Meltwind, o2h Ventures, SyndicateRoom, and Angel investors, with support from KPMG Acceleris.

From Five Alarm Bio 28 Feb 2023

CN Bio extends microphysiological system portfolio with PhysioMimix Single-Organ Higher Throughput System

CN Bio, a leading Organ-on-a-Chip (OOC) company that designs and manufactures single-and multi-organ microphysiological systems (MPS), today announced the commercial launch of the PhysioMimix™ Single-organ Higher Throughput (HT) System.

From CN Bio 28 Feb 2023

Difference between human and mouse lung tumor cells explains the discrepancy in cancer drug results

A small but significant metabolic difference between human and mouse lung tumor cells, has been discovered by Weill Cornell Medicine researchers, explaining a discrepancy in previous study results, and pointing toward new strategies for developing cancer treatments.

24 Feb 2023

Research identifies proteins that may contribute to onset of common metabolic diseases

New research has identified hundreds of proteins that might contribute to the onset of common, chronic metabolic diseases such as type 2 diabetes, and consequently pathways to potential treatments.

24 Feb 2023

A network of interacting proteins created to aid drug discovery

Scientists at Open Targets, EMBL's European Bioinformatics Institute, and GSK are revealing the shared basis of diseases using a map of interacting human proteins.

24 Feb 2023

Ingenza appoints new Strategic Business Advisor

Ingenza is excited to welcome Dr Mark Chadwick to the team as Strategic Business Advisor. Mark will bring extensive industry expertise to his new position at Ingenza, acquired over 30 years from a variety of roles within small growth companies, covering the areas of biotechnology, drug discovery and drug development.

23 Feb 2023

Drug Discovery News and Research

Further Reading

UK Government names two leaders to spearhead new Dementia Mission

£3 million funding to support the development of new antimicrobials for cystic fibrosis patients

Understanding how cells adjust in real time to withstand stresses on our health

CN Bio appoints Deepak Singh as Vice President of Sales and Marketing

Study identifies a potential new treatment approach for acute myeloid leukemia

Breakthrough drug works against all the main types of primary bone cancer

BioInfect: Bringing the best brains to the challenge of antimicrobial resistance

Antiverse raises funding and demonstrates therapeutic antibody identification with AI-driven drug discovery platform

New funding to accelerate development of potential anti-cancer compound into the clinic

First small molecules designed to stimulate immune cells against neuroblastoma

St. Jude researchers show how drug makers can avoid toxicity and resistance

Five Alarm Bio, Focused on Minimising the Effects of Aging in Humans, Raises Seed Investment

CN Bio extends microphysiological system portfolio with PhysioMimix Single-Organ Higher Throughput System

Difference between human and mouse lung tumor cells explains the discrepancy in cancer drug results

Research identifies proteins that may contribute to onset of common metabolic diseases

A network of interacting proteins created to aid drug discovery

Ingenza appoints new Strategic Business Advisor

New prototype treatment proves effective against the venom of African and Asian elapid snakes

Novel fatty liver organoid models could aid in drug discovery and testing

Mount Sinai study sheds new light on the role of DNA methylation in Alzheimer's disease

Event guide: World ADC Asia eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo